Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

NCT04213209 · clinicaltrials.gov ↗

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T Cell Lymphoma
Pediatric Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin (Genetical Recombination)

Sponsor

Takeda